US Patent Issued to DONG-A UNIVERSITY RESEARCH FOUNDATION FOR INDUSTRY-ACADEMY COOPERATION on Sept. 15 for "Anticancer adjuvant and pharmaceutical composition for treating anticancer-agent-resistant cancer, and kit comprising same" (South Korean Inventor)

ALEXANDRIA, Va., Sept. 15 -- United States Patent no. 12,735,704, issued on Sept. 15, was assigned to DONG-A UNIVERSITY RESEARCH FOUNDATION FOR INDUSTRY-ACADEMY COOPERATION (Busan, South Korea).

"Anticancer adjuvant and pharmaceutical composition for treating anticancer-agent-resistant cancer, and kit comprising same" was invented by Tae Hong Kang (Busan, South Korea).

According to the abstract* released by the U.S. Patent & Trademark Office: "An anticancer adjuvant for treating anticancer-agent-resistant cancer includes a tristetraprolin inhibitor. If resistance to DNA replication inhibitory anticancer agents is exhibited, a substance for inhibiting the activity of tristetraprolin can be included as an anticancer adjuvant so as to maximi...